| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/26/2006 | EP1683520A2 Water-soluble paclitaxel produgs |
| 07/26/2006 | EP1682890A2 Screening assays and methods of tumor treatment |
| 07/26/2006 | EP1682579A1 Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| 07/26/2006 | EP1682575A1 Igf-i responsive gene and use thereof |
| 07/26/2006 | EP1682571A1 A bidentate motif and methods of use |
| 07/26/2006 | EP1682570A1 A binding motif and methods of regulating cell function |
| 07/26/2006 | EP1682565A1 Iap nucleobase oligomers and oligomeric complexes and uses thereof |
| 07/26/2006 | EP1682555A1 Macrocyclic kinase inhibitors |
| 07/26/2006 | EP1682552A1 Tocopherol-modified therapeutic drug compounds |
| 07/26/2006 | EP1682548A1 Pyridopyrimidinones |
| 07/26/2006 | EP1682546A1 Peptidomimetic compounds, stereoselective process for their preparation, their use as biologically active synthetic intermediates |
| 07/26/2006 | EP1682538A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications |
| 07/26/2006 | EP1682524A1 Novel keto-oxadiazole derivatives as cathepsin inhibitors |
| 07/26/2006 | EP1682514A1 11- o-methylgeldanamycin compounds |
| 07/26/2006 | EP1682495A1 Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| 07/26/2006 | EP1682183A2 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
| 07/26/2006 | EP1682179A2 Enhanced b cell cytotoxicity of cdim binding antibody |
| 07/26/2006 | EP1682178A2 Methods of therapy for cancers expressing the cd40 antigen |
| 07/26/2006 | EP1682165A1 Use of interferon-tau in medicine |
| 07/26/2006 | EP1682153A2 Methods of modulating angiogenesis and cancer cell proliferation |
| 07/26/2006 | EP1682140A2 Methods of use of thrombin receptor antagonists |
| 07/26/2006 | EP1682138A2 Heterocyclic inhibitors of mek and methods of use thereof |
| 07/26/2006 | EP1682131A1 Cci-779 for treating mantle cell lymphoma |
| 07/26/2006 | EP1682126A1 Substituted benzazoles and use thereof as inhibitors of raf kinase |
| 07/26/2006 | EP1682119A1 Discodermolide compositions |
| 07/26/2006 | EP1682115A2 Hif-1 inhibitors and methods of use thereof |
| 07/26/2006 | EP1682107A1 Anti-tumour terpene compounds |
| 07/26/2006 | EP1513863B1 Platinum complexes containing chemically modified bile acids, having antitumor activity |
| 07/26/2006 | EP1513839B1 3-substituted quinuclidines and their use |
| 07/26/2006 | EP1414447B1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 07/26/2006 | EP1397105B1 Compositions for inhibiting angiogenesis |
| 07/26/2006 | EP1390543B1 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 07/26/2006 | EP1383539B1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 07/26/2006 | EP1373215B1 Geldanamycin derivatives useful for treating cancer |
| 07/26/2006 | EP1353687B1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 07/26/2006 | EP1263784B1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 07/26/2006 | EP1257297B1 Compositions and methods for treatemnt of angiogenesis in pathological lesions |
| 07/26/2006 | EP1240313B1 Homologue enzymes of human heparanase and splice variants thereof |
| 07/26/2006 | EP1082338B1 17 beta-nitro-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 07/26/2006 | EP1072273B1 Vascularization inhibitors |
| 07/26/2006 | CN1809583A Antisense oligonucleotides that inhibit expression of hif-1 |
| 07/26/2006 | CN1809570A [1,2,4 ]triazolo [1,5-a]pyrimidin-2-ylurea derivative and use thereof |
| 07/26/2006 | CN1809569A Pyrimido compounds |
| 07/26/2006 | CN1809565A Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 07/26/2006 | CN1809564A Pyrrolodihydroisoquinolines as PDE10 inhibitors |
| 07/26/2006 | CN1809563A Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| 07/26/2006 | CN1809557A 化合物 Compound |
| 07/26/2006 | CN1809555A Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases |
| 07/26/2006 | CN1809551A Flavanone compound and uses thereof |
| 07/26/2006 | CN1809541A Aniline derivatives |
| 07/26/2006 | CN1809540A Inhibitors of Akt activity |
| 07/26/2006 | CN1809375A Apoptosis inducing agent and method of inducing apoptosis |
| 07/26/2006 | CN1809365A Use of adenosine receptor agonists in therapy |
| 07/26/2006 | CN1809362A Substituted 1,4-diazepines and uses thereof |
| 07/26/2006 | CN1809360A 4-anilino-quinazoline derivatives as antiproliferative agents |
| 07/26/2006 | CN1809346A Preparation of pyrrolidine-1,2-dicarboxanilide derivatives for use as factor XA and VIIA inhibiting antithrombotic agents, comprises reacting pyrrolidine-2-carboxylic acid with phenyl isocyanate then |
| 07/26/2006 | CN1807454A GIBC gene and its coded protein and uses |
| 07/26/2006 | CN1807435A Water soluble phosphate ester salt ofú¿Zú®-3'-hydroxy-3,4',5-trimethoxydiphenyl ethylene, and its preparation method ,pharmaceutical composition and uses |
| 07/26/2006 | CN1807429A Use of fern in extracting harringtonine or homoharringtonine |
| 07/26/2006 | CN1807405A Charles ketone oxime and its composition , preparation method and uses |
| 07/26/2006 | CN1807404A Resveratrol derivative and its production method and uses |
| 07/26/2006 | CN1807403A Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use |
| 07/26/2006 | CN1807393A Apoptosis inhibitor |
| 07/26/2006 | CN1807391A Carboxyl substituted resveratrol analog compound and its preparation method |
| 07/26/2006 | CN1806841A Medicine for treating stomach cancer, colon cancer and rectum cancer and method for preparing the same |
| 07/26/2006 | CN1806818A Patchouli leaf juice for treating cancer and/or tumor |
| 07/26/2006 | CN1806809A Organic germanium injection and preparation process thereof |
| 07/26/2006 | CN1806794A GM-CSF targeted medicine liposome for resisting acute myelogenous leukemia and preparation method thereof |
| 07/26/2006 | CN1806574A Method for preparing tumor mutation-resisting yoghourt with micron ash tree pollen, pine pollen, bee pollen and ganoderma lucidum spore powder |
| 07/26/2006 | CN1266274C Trichosanthin suicide ENH-TCS, recombination vector and application thereof |
| 07/26/2006 | CN1266164C Lucid ganoderma spore powder polysaccharide, production method and use |
| 07/26/2006 | CN1265840C Immunity coupler of containing monoclonal antibody Fab' segment of anti TV type collagenase poly glutamic acid-blemycin A5 |
| 07/26/2006 | CN1265833C Chinese medicinal preparation for treating cancer |
| 07/26/2006 | CN1265831C Compound ginseng saponin biological preparation for inhibiting tumour and its preparation method |
| 07/26/2006 | CN1265821C Medicine for treating liver cancer and its preparation method |
| 07/26/2006 | CN1265808C Combination of medication for anti herpes virus and its application |
| 07/26/2006 | CN1265792C Use of niacin alkyl ester containing alkyl chain with 8 to 22 carbon atom in preparation of medicine for increasing leptin |
| 07/26/2006 | CN1265787C Liver-targeting mitomycin magnetic nano-particle and its preparation and application in medicine preparation |
| 07/26/2006 | CN1265786C Use of a compound and paclitaxel in preparation of medicine for treating cancer |
| 07/25/2006 | US7081532 N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-ylmethyl-benzamide or salt; antiproliferative agent |
| 07/25/2006 | US7081524 O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates |
| 07/25/2006 | US7081518 For the diagnosis and therapy of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin |
| 07/25/2006 | US7081513 Peptides having Chemotaxis Inhibitory Protein from Staphylococcus aureus (CHIPS) activity for diagnosis, prophylaxis and treatment of inflammation and HIV |
| 07/25/2006 | US7081475 Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well as tumor formation in a subject are described herein as anticancer agents |
| 07/25/2006 | US7081469 Therapy for neovascularization; antitumor agents; vision defects; antidiabetic agents; antiarthritic agents |
| 07/25/2006 | US7081468 Angiogenesis inhibitors; antitumor agents; skin disorders; antiarthritic agents |
| 07/25/2006 | US7081466 anticarcinogenic agents with improved efficacy against multidrug resistant tumors; improved oral bioavailability and side effect reduction |
| 07/25/2006 | US7081464 enzyme inhibitors of tumor necrosis factor alpha and phosphodiesterase; anticachetic, antiasthmatic, antiinflammatory agents |
| 07/25/2006 | US7081461 Quinazoline compounds and pharmaceutical compositions containing them |
| 07/25/2006 | US7081460 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 07/25/2006 | US7081459 1-substituted pyridine-2-ones or 2-substituted pyridazin-3-ones; anticarcinogenic agents for breast and prostate cancer; contraceptives; endometriosis, benign prostatic hypertophy |
| 07/25/2006 | US7081457 Contraceptives; hormone replacement therapy |
| 07/25/2006 | US7081452 Diagnosis, therapy, image of celluloar disorders; antitumor agents |
| 07/25/2006 | US7081449 Induce apoptosis; anticancer agents |
| 07/25/2006 | US7081443 A fusion proteins comprising a cyclic peptide linked to a receptor as a cell growth factors, promoting cell proliferation, cell antiproliferative agents; soluble, potent |
| 07/25/2006 | US7081351 Immobilized and labeled; detection cell differentiation, cell proliferation; prevent binding to fibroblast growth factor |
| 07/25/2006 | CA2242354C Pyrrolopyrimidines and processes for their preparation |
| 07/25/2006 | CA2161138C Oxidation products of cephalomannine |
| 07/25/2006 | CA2133140C Isoxazole derivatives |
| 07/21/2006 | CA2494209A1 Radiosensitizer formulations and methods for use |